Head-to-head · free
Novartis AG vs Ovid Therapeutics Inc.
NVS vs OVID — return on capital, cash generation, margins and balance sheet side by side.
NVS
2 / 3
measures where NVS leads
OVID
1 / 3
measures where OVID leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | NVS | OVID · FY2025 |
|---|---|---|
| Revenue | — | $7.3M |
| Net income | — | (17.4M) |
| Revenue growth (yearly, multi-year) | — | -68.1% |
| Free cash flow | — | (38.3M) |
| Free cash flow margin | — | -528.6% |
| Net cash / (debt) | — | — |
| ROIC | 18.6% | — |
| Return on equity | 31.0% | -17.5% |
| Gross margin | 75.8% | — |
| Operating margin | 31.1% | -585.2% |
| Net debt / EBITDA | 0.96x | 0.31x |
Figures are as reported by each company; latest fiscal year shown.
Where Ovid Therapeutics Inc.'s cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free